Fig. 6.

Evolution of clonal and subclonal mutations in CSF and plasma after treatment. A Percentage of clonal and subclonal mutations at baseline and 8 weeks after treatment in CSF and plasma. The definition of clonal and subclonal mutations is based on their baseline VAFs (clonal: VAF ≥ 25% * maxVAF in baseline samples) and any acquired mutations after treatment are classified into subclonal subgroups. B Kaplan-Meier curves of intracranial and extracranial progression-free survival according to clonal mutations and EGFR clones 8 weeks after treatment. P-values were calculated using the log-rank test. Abbreviations: CSF, cerebrospinal fluid; HR, hazards ratio; PFS, progression-free survival